KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Biogen (BIIB) Net Income towards Common Stockholders (2016 - 2025)

Biogen (BIIB) has 17 years of Net Income towards Common Stockholders data on record, last reported at -$48.9 million in Q4 2025.

  • For Q4 2025, Net Income towards Common Stockholders fell 118.34% year-over-year to -$48.9 million; the TTM value through Dec 2025 reached $1.3 billion, down 20.79%, while the annual FY2025 figure was $1.3 billion, 20.79% down from the prior year.
  • Net Income towards Common Stockholders reached -$48.9 million in Q4 2025 per BIIB's latest filing, down from $466.5 million in the prior quarter.
  • Across five years, Net Income towards Common Stockholders topped out at $1.1 billion in Q3 2022 and bottomed at -$137.1 million in Q3 2023.
  • Average Net Income towards Common Stockholders over 5 years is $399.2 million, with a median of $417.6 million recorded in 2021.
  • Peak YoY movement for Net Income towards Common Stockholders: tumbled 128.78% in 2021, then surged 948.37% in 2022.
  • A 5-year view of Net Income towards Common Stockholders shows it stood at -$101.8 million in 2021, then surged by 649.12% to $559.0 million in 2022, then plummeted by 47.84% to $291.6 million in 2023, then fell by 8.54% to $266.7 million in 2024, then crashed by 118.34% to -$48.9 million in 2025.
  • Per Business Quant database, its latest 3 readings for Net Income towards Common Stockholders were -$48.9 million in Q4 2025, $466.5 million in Q3 2025, and $634.8 million in Q2 2025.